EGFR and breast carcinoma: Therefore, in clinical settings, EGFR inhibitors have been efficacious for the treatment of tumors associated with EGFR overexpression: lapatinib, an inhibitor of the kinase domain of EGFR, is used for metastatic breast cancers in conjunction with conventional cytotoxic drugs [8, 9].